In this episode of Visionary Voices, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, joins us to explore how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...

In this interview, we speak with Dr Anthony Caggiano, Chief Medical Officer and Head of R&D at Cognition Therapeutics, and Lisa Ricciardi, the company’s Chief Executive Officer. They discuss the design and findings of the phase II SHINE trial evaluating zervimesine (CT-1812) in mild to moderate Alzheimer’s disease, including important biomarker and clinical insights presented at recent international conferences. They also reflect on promising data from a study in dementia with Lewy bodies (DLB) and how these results are shaping the company’s next steps.

Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...

A new study published in Nature Neuroscience1 has uncovered significant insights into the progression of Alzheimer’s disease (AD), providing a new understanding of how the disease damages the brain. Funded by the National Institutes of Health (NIH) and led by researchers from the Allen Institute, this study used advanced brain mapping and genetic tools to explore the cellular-level changes that occur throughout AD. The findings reveal that Alzheimer's progresses in two distinct phases, offering potential avenues for early diagnosis and treatment strategies.

In our next expert Q&A we are delighted to welcome Prof. Bengt Winblad. Prof. Winblad is a prominent figure in geriatric medicine and Alzheimer's research, having served as Head of the Division of Neurogeriatrics at Karolinska Institutet and ...

The novel severe acute respiratory syndrome coronavirus 2 has caused a worldwide pandemic, and its impact on healthcare systems around the world is still being investigated. The potential effect of coronavirus disease 2019 (COVID-19) on people living with dementia and the ability ...

Gastroesophageal reflux disease (GERD) is a chronic condition affecting over 750 million people globally.1 The disease causes acid from the stomach to reflux into the oesophagus, leading to epigastric discomfort, cough, sore throat and chest pain.1 Left untreated, this disease can ...

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia.1 It is characterized by two hallmark pathologies: the deposition of amyloid-β plaques and the neurofibrillary tangles of hyperphosphorylated tau.1 The clinical presentation of AD ...